{"id":3333,"date":"2026-11-07T10:27:30","date_gmt":"2026-11-07T01:27:30","guid":{"rendered":"https:\/\/teamoncology.com\/echo\/96th\/"},"modified":"2026-11-07T10:29:54","modified_gmt":"2026-11-07T01:29:54","slug":"96th","status":"publish","type":"page","link":"https:\/\/teamoncology.com\/en\/echo\/96th\/","title":{"rendered":"96th ECHO ONE Clinic"},"content":{"rendered":"\n
<\/span>
\n

96th ECHO ONE Clinic<\/h1>\n\n\n\n
\n
\n
Theme<\/span><\/dt>\n\n\n\n
\n

Eye Toxicity<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Date and Time<\/span><\/dt>\n\n\n\n
\n

Thursday, November 19th, 2026, 7 p.m. in Japan and Korea, 6 p.m. in Taiwan and the Philippines, 5 p.m. in Thailand and Vietnam, and 4 a.m. in Houston *About 1 Hour<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Language<\/span><\/dt>\n\n\n\n
\n

Japanese *AI-powered live translated captions can be enabled for various languages within Zoom meetings.<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Organized by<\/span><\/dt>\n\n\n\n
\n

Project ECHO ONE Japan Team<\/p>\n<\/div><\/dd>\n<\/div>\n<\/dl>\n<\/div><\/div>\n

\n
\"\"<\/figure>\n<\/div>\n
<\/div>\n\n
\n
\n
Mentor<\/span><\/dt>\n\n\n\n
\n

Dr. Hiroya Kashiwagi (Shizuoka Cancer Center)<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Case Presenter<\/span><\/dt>\n\n\n\n
\n

Mr. Yasuhiro Oda (Toranomon Hospital)<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Commentator<\/span><\/dt>\n\n\n\n
\n

Dr. Takahiro Kogawa (The Cancer Institute Hospital of JFCR)<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Facilitator<\/span><\/dt>\n\n\n\n
\n

Ms. Sakiko Aso (Shizuoka Cancer Center)<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Participation Capacity<\/span><\/dt>\n\n\n\n
\n

100 People<\/p>\n<\/div><\/dd>\n<\/div>\n\n\n\n

\n
Participation Fee<\/span><\/dt>\n\n\n\n
\n

Free<\/p>\n<\/div><\/dd>\n<\/div>\n<\/dl>\n\n

<\/p>\n\n

\n
<\/i>
\n

Although eye toxicity rarely affects patient survival directly, it significantly impacts patients’ quality of life (QOL) and treatment continuation. In recent years, various forms of eye toxicity caused by molecularly targeted therapies and antibody-drug conjugates (ADCs) have been reported, drawing increasing attention from healthcare professionals as important adverse events in cancer care. In this session, through case studies, we will learn about the characteristics, prevention, and management of eye toxicity, as well as key points for multidisciplinary collaboration.<\/p>\n<\/div><\/div>\n<\/blockquote>\n\n

<\/div>\n\n

Application Form<\/h2>\n\n